Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun;96(25):e7238.
doi: 10.1097/MD.0000000000007238.

Recurrent Campylobacter jejuni bacteremia in a patient with hypogammaglobulinemia: A case report

Affiliations
Case Reports

Recurrent Campylobacter jejuni bacteremia in a patient with hypogammaglobulinemia: A case report

Youie Kim et al. Medicine (Baltimore). 2017 Jun.

Abstract

Rationale: Although some cases of recurrent bacteremia due to Campylobacter jejuni have been reported in immunocompromised patients, antibiotic treatment strategies to eradicate C. jejuni and prevent recurrent infections in immunocompromised patients have not been established. Authors' experience of such rare cases should be shared for improving patients' outcomes.

Patient concerns: An 18-year-old boy with hypogammaglobulinemia, who received intravenous immunoglobulin replacement therapy every 3 weeks, was admitted to hospital repeatedly due to recurrent diarrhea and cellulitis of the leg.

Diagnoses: The patient was admitted 6 times, and among them, C. jejuni was isolated from blood cultures 4 times and stool cultures 2 times.

Interventions: The patient experienced recurrent C. jejuni enteritis and bacteremia 5 times despite macrolide therapy. Doxycycline was administered for 3 months after the fifth admission.

Outcomes: Ten months after the completion of doxycycline therapy for 3 months, C. jejuni enteritis relapsed; however, since then, recurrent infection has not occurred for 10 months.

Lessons: Immunocompromised patients can experience recurrent C. jejuni infection despite prolonged antibiotic therapy. Further studies to establish appropriate antibiotic therapy for eradicating colonized C. jejuni and preventing recurrent infection are needed.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
The clinical course of recurrent Campylobacter jejuni infection.

References

    1. Zakhour R, Heresi GP, Murphy JR. Cherry JD, Demmler-Harrison GJ, Kaplan SL, Hotez P, Steinbach WJ. Campylobacter jejuni. Fiegin and Cherry's Pediatric Infectious Diseases. Philadelphia, PA: Saunders: 2014;1644–57.
    1. Janssen R, Krogfelt KA, Cawthraw SA, et al. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev 2008;21:505–18. - PMC - PubMed
    1. Van der Hilst JC, Smits BW, van der Meer JW. Hypogammaglobulinaemia: cumulative experience in 49 patients in a tertiary care institution. Neth J Med 2002;60:140–7. - PubMed
    1. Jirapongsananuruk O, Wanotayan K, Phongsamart W, et al. Recurrent Campylobacter lari bacteremia in X-linked agammaglobulinemia: a case report and review. Asian Pac J Allergy Immunol 2006;24:171–4. - PubMed
    1. Kerstens PJ, Endtz HP, Meis JF, et al. Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia. Eur J Clin Microbiol Infect Dis 1992;11:842–7. - PubMed

Publication types

MeSH terms

Substances